ProQR Therapeutics N.V. (PRQR)’s Financial Results Comparing With Denali Therapeutics Inc. (NASDAQ:DNLI)

Both ProQR Therapeutics N.V. (NASDAQ:PRQR) and Denali Therapeutics Inc. (NASDAQ:DNLI) are Biotechnology companies, competing one another. We will compare their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProQR Therapeutics N.V. N/A 0.00 N/A -1.29 0.00
Denali Therapeutics Inc. 3.48M 544.56 136.66M -1.45 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for ProQR Therapeutics N.V. and Denali Therapeutics Inc.


Table 2 shows us ProQR Therapeutics N.V. and Denali Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
ProQR Therapeutics N.V. 0.00% -72.6% -56%
Denali Therapeutics Inc. -3,927.01% -27.9% -24.7%


The Current Ratio and a Quick Ratio of ProQR Therapeutics N.V. are 11.4 and 11.4. Competitively, Denali Therapeutics Inc. has 12.1 and 12.1 for Current and Quick Ratio. Denali Therapeutics Inc.’s better ability to pay short and long-term obligations than ProQR Therapeutics N.V.

Analyst Ratings

ProQR Therapeutics N.V. and Denali Therapeutics Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ProQR Therapeutics N.V. 0 0 2 3.00
Denali Therapeutics Inc. 0 0 0 0.00

ProQR Therapeutics N.V.’s upside potential is 152.36% at a $37.5 consensus target price.

Insider & Institutional Ownership

ProQR Therapeutics N.V. and Denali Therapeutics Inc. has shares held by institutional investors as follows: 63.5% and 83.3%. ProQR Therapeutics N.V.’s share held by insiders are 20.62%. Comparatively, Denali Therapeutics Inc. has 0.1% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ProQR Therapeutics N.V. -10.44% -15.07% -8.47% 162.62% 478.64% 429.3%
Denali Therapeutics Inc. 5.53% 16.47% 10.43% 10.31% 0% 29.35%

For the past year ProQR Therapeutics N.V. has stronger performance than Denali Therapeutics Inc.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.